2. Bumbacea D, Pulka G, Dymek A et al. Fluticasone propionate/formoterol fumarate combination therapy is more effective than fluticasone propionate alone in the treatment of asthma. Abstracto presentado en la SER, 18-22.09 2010 en Barcelona, España.
3. Partridge MR, van der Molen T, Myrseth SE et al. Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study. BMC Pulm Med 2006;6:13.
4. Cazzoletti L, Marcon A, Janson C et al. Asthma control in Europe: a real-world evaluation based on an international population-based study. J Allergy Clin Immunol 2007;120:1360-7.
5. Buhl R, Vogelmeier C. Budesonide/Formoterol maintenance and reliever therapy: a new treatment approach for adult patients with asthma. Curr Med Res Opin 2007;23:1867-78.
6. IMS Health, UK; base de datos MIDAS, aceso en mayo de 2010.
7. Berger WE. The use of inhaled formoterol in the treatment of asthma, Ann Allergy Asthma Immunol. 2006;97:24-33.
8. Prenner BM. Formoterol dry-powder inhaler for the treatment of asthma and chronic obstructive pulmonary disease. Expert Opin. Pharmacother. 2007; 8(17):3069-3084.
9. Chrystyn H, Price D. Not all asthma inhalers are the same: factors to consider when prescribing an inhaler. Prim Care Res J 2009;18:243-9.
10. Price D, Ali M, Burden A et al. Device type and real-world effectiveness of combination therapy. Abstracto presentado en la SER, 18-22.09 2010 en Barcelona, España.
Todas las traducciones se han completado por medio de PR Newswire
Si desea más información contacte con: Bily Kuo, Bily.Kuo@mundipharma.co.uk, +44(0)1223-397-118; Wioletta Niznik, WNiznik@webershandwick.com, +44(0)2070-670-202